Table 3.

Seroconversion rates after vaccination with M-M-R_II, alone or with other routine vaccinations

	Seroconversion rates (%)
Category	Measles	Mumps	Rubella
By age groupa
<12 monthsb	87.4	92.3	91.2
12 months–3 yearsc	92.8–100	91.1–100	92.8–100
4–6 yearsd	99.3–100	100	99.4–100
≥7 yearse	96.0–100	94.5–100f	91.3–100
By dose number, 12 months–6 years
First doseg	87.5–100	90.0–100	92.0–100
Second doseh	98.4–100	98.6–100	99.6–100
Concomitant use with other vaccine(s), first dose
M-M-RII alonei,j,k	90.4–100	90.0–100	90.0–100
Diphtheria-tetanus-pertussis and (oral or inactivated) poliovirus (DTaP)i,j,l	95.0–100	97.0–100	92.0–100
Haemophilus influenzae type b (Hib)i,m	95.7–99.4	98.4–100	97.0–100
Hepatitis Ai,n	96.3–100	97.6–100	98.3–100
Hepatitis Bj,o	100	100	100
Influenzai,p	97.0	>96.0	>97.0
Japanese encephalitisi,q	97.6–100	98.8–99.5	100
Varicellai,r	87.5–100	79.5–100	92.8–100
Concomitant use with other vaccine(s), second dose
M-M-RII alonei,s	99.3	100	100
DTaPi,j,t	98.9–100	98.9–100	99.4–100
Hepatitis Bj,o	100	100	100
Varicellai,u	100	100	100
Alternative administration methodsv
Intramuscularw	94.3	97.7	98.1

Assays used and time for collection of sera may have differed across the studies. Some studies are reported in more than one of the references cited.

^aSubjects ≤3 years of age received a first or first and second dose of M-M-R_II; subjects ≥4 years of age received a second or possible third dose of M-M-R_II.

^bReference: ¹⁴⁹

^cReferences: ^{47,51,52,54,58-62,64,65,67-70,73,74,76,77,79-83,85-87,91,92,122,123,125-128,150}

^dReferences: ^{49,66,72,104,129,130,151,152}

^eReferences: ^{53,88-90,121,131-134,153,154}

^fMost studies in this age group reported a range of 94.5–100% for mumps seropositivity. The authors of the paper that reported the single low outlier of 65% stated that ‘the mumps antibody levels obtained with the present tests may not accurately reflect actual immunity.’¹⁵³

^gReferences: ^{47,51,52,54,58-62,64,65,67-70,73,74,76,77,79-83,85-87,91,92,104,122,123,125-128,150}

^hReferences: ^{49,66,67,72,119,129,130,151,152}

ⁱRanges include data from participants 12 months to 6 years of age.

^jRanges include data from participants ≥7 years of age.

^kReferences: ^{46,88-90,104-115,118,121,131-134,149,153-156}

^lReferences: ^53,54,77,86

^mReferences: ^51,60,74,82

ⁿReferences: ^{47,52,59,62,67-69,76,119,127-129,150}

^oReference: ⁵³

^pReference: ⁷⁰

^qReference: ⁶¹

^rReferences: ^{55,57,58,60,64,65,70,73,76,79-81,83,85,86,91,92,122,125,126}

^sReferences: ^67,119,151

^tReferences: ^{49,53,66,129,130}

^uReferences: ^72,152

^vTwo studies assessed the safety and immunogenicity of M-M-R_II delivered by alternative, non-licensed methods – aerosol or needle-free jet injector.^90,134 Immunogenicity by aerosol administration was 100%, 98.3%, and 100% for measles, mumps, and rubella, respectively. Immunogenicity in the needle-free jet injector study was reported as geometric mean ratios (GMR) for each antibody compared to a positive control. The values for the GMR at week 12 by needle-jet injector versus subcutaneous administration for measles, mumps, and rubella were 0.74 versus 0.89, 0.94 versus 0.90, and 2.07 versus 1.87, respectively.

^wReference: ⁵⁸